Luliconazole Stability Evaluation Using Solvent Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of pharmaceutical preparations containing luliconazole is compromised due to the production of stereoisomers like the SE form and Z form, and the amide form, which is not well understood, making it difficult to predict stability during storage based on solvent type, and the amide form is rarely produced under accelerated or severe tests.
Innovation Solution
A method to evaluate the stability of luliconazole pharmaceutical preparations by measuring the production of SE, Z, and amide forms after storage under severe or accelerated conditions, with the goal of keeping each form below 5% by weight, using specific solvents like polyhydric alcohols, dibasic acid esters, and heterocyclic solvents to control amide form production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If luliconazole is used as an active ingredient in pharmaceutical preparation, then antifungal activity is achieved, but stability is compromised due to production of stereoisomers and amide form
Solution Approach 1:
The patent changes the physical and chemical parameters of the preparation system by introducing specific solvents (polyhydric alcohols, dibasic acid esters, heterocyclic solvents) and co-solvents to modify the chemical environment. This alters the reaction parameters that lead to amide form production, thereby controlling degradation while maintaining the antifungal activity of luliconazole.
2Measurement precision
If accelerated test or severe test is performed on luliconazole, then production of SE form and Z form is detected, but amide form is hardly produced making it difficult to evaluate stability
Solution Approach 1:
The patent applies preliminary action by pre-establishing the relationship between solvent types and amide form production through systematic investigation before actual stability evaluation. By categorizing solvents into those that promote amide form production and those that suppress it, the method enables reliable prediction and evaluation of stability without relying solely on accelerated tests that fail to produce amide form.
3Ease of manufacture
If solvent type is selected without considering amide form production, then manufacturing is simplified, but stability cannot be predicted or controlled
Solution Approach 1:
The patent transforms the solvent selection process by introducing new classification parameters based on amide form production characteristics. Solvents are categorized into Group 1 (promote amide form), Group 2 (suppress amide form), and Group 3 (co-solvents). This parameter-based classification system maintains manufacturing simplicity while enabling stable formulation design through informed solvent selection.
4Device complexity
If amide form production is not monitored, then evaluation process is simpler, but stability improvement cannot be achieved
Solution Approach 1:
The patent implements feedback by establishing a closed-loop evaluation system that measures amide form production and uses this information to optimize formulation. The method provides quantitative feedback on solvent performance based on amide form generation, enabling iterative improvement of preparation stability while maintaining a manageable evaluation process through systematic measurement protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures high stability of luliconazole preparations by controlling the production of all forms, particularly the amide form, which is difficult to produce and affects antifungal activity, thereby maintaining the effectiveness of the pharmaceutical.
Implementation Method 1
it is considered that this amide form is produced by the addition of water with respect to a cyano group of the luliconazole
Data Source
AI summary
Disclosed is a method of evaluating stability of a pharmaceutical preparation containing luliconazole. The method includes measuring an amount of production of an SE form of luliconazole represented by following formula (2), an amount of production of a Z form of luliconazole represented by following formula (3) and an amount of production of an amide form of luliconazole represented by following formula (1) after storage under a severe condition or an accelerated condition, and judging that the stability of the pharmaceutical preparation is high if each of the amount of production of the SE form, the amount of production of the Z form and the amount of production of the amide form is not more than 5% by weight with respect to a compounded amount of luliconazole.